On this page of StockholderLetter.com we present the latest annual shareholder letter from Cencora, Inc. — ticker symbol COR. Reading current and past COR letters to shareholders can bring important insights into the investment thesis.

 •  1/22/2026 Letter Continued (Full PDF)
 •  1/27/2023 COR Stockholder Letter
 •  1/29/2024 COR Stockholder Letter
 •  1/23/2025 COR Stockholder Letter
 •  More "Drugs & Pharmaceuticals" Category Stockholder Letters
 •  COR Benford's Law Stock Score = 25

COR Shareholder/Stockholder Letter Transcript:

Summary
Annual Report
2025

Table of
contents
03 About Cencora
05 CEO letter
11
Cencora highlights and strategic
overview
12 Management team
13 Board of Directors
14 GAAP/Non - GAAP financial measures
17 Corporate information
02

About
Cencora
Cencora is a leading global pharmaceutical solutions
organization centered on improving the lives of people
and animals around the world. We partner with
pharmaceutical innovators across the value chain to
facilitate and optimize market access to therapies.
Care providers depend on us for the secure, reliable
delivery of pharmaceuticals, healthcare products, and
solutions.
03

04

CEO letter
To our shareholders
Fiscal 2025 was a notable year for Cencora, as we delivered
strong financial performance and fortified our position as a
leading healthcare company, exemplified by the acquisition of
Retina Consultants of America (   RCA   ). The strength of our
enterprise is powered by our team members, who are
committed to our purpose and drive differentiated value for our
stakeholders.
We continue to execute our pharmaceutical-centric strategy,
steered by our strategic drivers and anchored in our growth
priorities, to serve our customers and ensure patient access to
the medications they need.
05
05



 1/22/2026 Letter Continued (Full PDF)